» Articles » PMID: 22096244

P-selectin Glycoprotein Ligand Regulates the Interaction of Multiple Myeloma Cells with the Bone Marrow Microenvironment

Abstract

Interactions between multiple myeloma (MM) cells and the BM microenvironment play a critical role in the pathogenesis of MM and in the development of drug resistance by MM cells. Selectins are involved in extravasation and homing of leukocytes to target organs. In the present study, we focused on adhesion dynamics that involve P-selectin glycoprotein ligand-1 (PSGL-1) on MM cells and its interaction with selectins in the BM microenvironment. We show that PSGL-1 is highly expressed on MM cells and regulates the adhesion and homing of MM cells to cells in the BM microenvironment in vitro and in vivo. This interaction involves both endothelial cells and BM stromal cells. Using loss-of-function studies and the small-molecule pan-selectin inhibitor GMI-1070, we show that PSGL-1 regulates the activation of integrins and downstream signaling. We also document that this interaction regulates MM-cell proliferation in coculture with BM microenvironmental cells and the development of drug resistance. Furthermore, inhibiting this interaction with GMI-1070 enhances the sensitization of MM cells to bortezomib in vitro and in vivo. These data highlight the critical contribution of PSGL-1 to the regulation of growth, dissemination, and drug resistance in MM in the context of the BM microenvironment.

Citing Articles

From Biology to Clinical Practice: The Bone Marrow Microenvironment in Multiple Myeloma.

Fotiou D, Katodritou E J Clin Med. 2025; 14(2.

PMID: 39860333 PMC: 11765558. DOI: 10.3390/jcm14020327.


A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy.

Peng M, Lu X, Guo J, Yin X, Zhang J, Li X Biomark Res. 2024; 12(1):151.

PMID: 39617949 PMC: 11610313. DOI: 10.1186/s40364-024-00693-8.


IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma.

Sun J, Corradini S, Azab F, Shokeen M, Muz B, Miari K Leukemia. 2024; 38(11):2355-2365.

PMID: 39215060 PMC: 11518999. DOI: 10.1038/s41375-024-02391-8.


Identification and validation of a platelet-related signature for predicting survival and drug sensitivity in multiple myeloma.

Lin Z, Wang Q, Zheng Z, Zhang B, Zhou S, Zheng D Front Pharmacol. 2024; 15:1377370.

PMID: 38818376 PMC: 11137312. DOI: 10.3389/fphar.2024.1377370.


Targeted therapy for multiple myeloma: an overview on CD138-based strategies.

Riccardi F, Tangredi C, Dal Bo M, Toffoli G Front Oncol. 2024; 14:1370854.

PMID: 38655136 PMC: 11035824. DOI: 10.3389/fonc.2024.1370854.


References
1.
Woodward J . Crossing the endothelium: E-selectin regulates tumor cell migration under flow conditions. Cell Adh Migr. 2009; 2(3):151-2. PMC: 2634092. DOI: 10.4161/cam.2.3.6820. View

2.
Kaila N, Thomas 4th B, Thakker P, Alvarez J, Camphausen R, Crommie D . Design and synthesis of sialyl Lewis x mimics as E-selectin inhibitors. Bioorg Med Chem Lett. 2001; 11(2):151-5. DOI: 10.1016/s0960-894x(00)00623-5. View

3.
Sperandio M, Smith M, Forlow S, Olson T, Xia L, McEver R . P-selectin glycoprotein ligand-1 mediates L-selectin-dependent leukocyte rolling in venules. J Exp Med. 2003; 197(10):1355-63. PMC: 2193782. DOI: 10.1084/jem.20021854. View

4.
Chng W, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K . Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007; 67(7):2982-9. DOI: 10.1158/0008-5472.CAN-06-4046. View

5.
Thoma G, Kinzy W, Bruns C, Patton J, Magnani J, Banteli R . Synthesis and biological evaluation of a potent E-selectin antagonist. J Med Chem. 1999; 42(23):4909-13. DOI: 10.1021/jm990422n. View